The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis

Williams, Adam N.; Woessner, Katharine M.

doi:10.1007/s11882-008-0041-7

Cited by 28 publications

(17 citation statements)

References 40 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eine spezifische orale Toleranzinduktion (SOTI) mit ASS kann den Krankheitsverlauf bei Patienten mit AERD positiv beeinflussen, es kommt zur Reduktion der chronischen Atemwegsentzündung, das Asthma wird stabilisiert, die Polyposis rezidiviert seltener. 37,38,41,54,62,64,79]). Die größte Erfahrung mit der SOTI hat die Arbeitsgruppe um Stevenson [4,21,38,64], die berichtet, dass F das Riechvermögen verbessert wird und die Anzahl notwendiger Nasennebenhöhlenrevisions-operationen sinkt, F Hospitalisationen wegen Asthma und die Einnahme notwendiger Asthmamedikamente (topische und systemische Steroide) reduziert werden und F sich die Lebensqualität bessert.…”

Section: Ass-toleranzinduktion Therapieoption Bei Patienten Mit Analgunclassified

“…Die Indikation zur SOTI wird üblicherweise gesehen bei Patienten mit AERD [38,79] F und persistierenden Symptomen trotz intensiver medikamentöser Therapie (intranasale Steroide , Leukotrienrezeptorantagonisten, ggf. Antirefluxtherapie) und/oder F mit rezidivierender Polyposis nasi, die wiederholte Operationen notwendig macht, und/oder F die häufig oder täglich Kortison systemisch einnehmen müssen, um nasale Symptome oder das Asthma zu kontrollieren, F ferner bei AERD Patienten, die aufgrund kardiovaskulärer, neurologischer oder rheumatischer Erkrankungen NSAID benötigen.…”

Section: Indikationunclassified

See 1 more Smart Citation

ASS-Toleranzinduktion

Weber

Trautmann²,

Randerath³

et al. 2012

HNO

View full text Add to dashboard Cite

Aspirin desensitization has established itself as an additional therapy option in the treatment of aspirin- exacerbated respiratory disease, recurrent chronic rhinosinusitis and nasal polyps. Inpatient treatment is strongly recommended due to the risk of life-threatening side effects. In addition, the necessary requirements, indications and contraindications should be carefully considered from a medicolegal perspective. A maintenance dose of 300 (-500) mg ASS is currently recommended. Indications include persisting symptoms despite intensive medical care and/or recurrent nasal polyps, leading to recurrent sinus operations and/or the need to take systemic corticosteroids in order to control nasal symptoms or asthma. If ASS intake is interrupted for more than 48 h, aspirin desensitization should be resumed to prevent renewed intolerance reactions.

show abstract

Section: Ass-toleranzinduktion Therapieoption Bei Patienten Mit Analgunclassified

Section: Indikationunclassified

ASS-Toleranzinduktion

Weber

Trautmann²,

Randerath³

et al. 2012

HNO

View full text Add to dashboard Cite

show abstract

“…141 Consequently, aspirin desensitization is recommended as an adjunctive therapy in the management of patients with Samter's triad. 142 Immunotherapy As mentioned above, there is a strong association between allergic rhinitis and CRS. Immunotherapy is an established treatment for allergic rhinitis, including patients refractory to conventional pharmacologic treatment.…”

Section: Aspirin Desensitizationmentioning

confidence: 99%

Diagnosis and Management of Chronic Rhinosinusitis in Adults

Marple

Stankiewicz

Baroody

et al. 2009

Postgraduate Medicine

View full text Add to dashboard Cite

Chronic rhinosinusitis (CRS) is characterized by mucosal inflammation affecting both the nasal cavity and paranasal sinuses; its causes are potentially numerous, disparate, and frequently overlapping. The more common conditions that are associated with CRS are perennial allergic and nonallergic rhinitis, nasal polyps, and anatomical mechanical obstruction (septum/turbinate issues). Other less common etiologies include inflammation (eg, from superantigens), fungal sinusitis or bacterial sinusitis with or without associated biofilm formation, gastroesophageal reflux, smoke and other environmental exposures, immune deficiencies, genetics, and aspirin-exacerbated respiratory disease. A diagnosis of CRS is strongly suggested by a history of symptoms (eg, congestion and/or fullness; nasal obstruction, blockage, discharge, and/or purulence; discolored postnasal discharge; hyposmia/anosmia; facial pain and/or pressure) and their duration for > 3 months. A definitive diagnosis requires physical evidence of mucosal swelling or discharge appreciated during physical examination coupled with CT imaging if inflammation does not involve the middle meatus or ethmoid bulla. Multivariant causation makes the diagnosis of CRS and selection of treatment complex. Furthermore, various types of health care providers including ear, nose, and throat (ENT) specialists, allergists, primary care physicians, and pulmonologists treat CRS, and each is likely to have a different approach. A structured approach to the diagnosis and management of CRS can help streamline and standardize care no matter where patients present for evaluation and treatment. A 2008 Working Group on CRS in Adults, supported by the American Academy of Otolaryngic Allergy (AAOA), developed a series of algorithms for the differential diagnosis and treatment of CRS in adults, based on the evolving understanding of CRS as an inflammatory disease. The algorithms presented in this paper address an approach for all CRS patients as well as approaches for those with nasal polyps, edema observed on nasal endoscopy, purulence observed on nasal endoscopy, an abnormal history and physical examination, and an abnormal history and normal physical examination.

show abstract

“…Every effort should be made to control concomitant allergic inflammation through avoidance and immunotherapy [11•]. Additionally, aspirin desensitization has been shown to decrease the need for revision ESS and should be considered in patients with aspirin-exacerbated respiratory disease with a history of multiple sinus surgeries [16].…”

Section: Aspirin Sensitivitymentioning

confidence: 99%

Rhinosinusitis and Comorbidities

Ryan

Brooks

2010

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

A variety of systemic conditions impact the incidence, severity, prognosis, and treatment approach in patients with chronic rhinosinusitis (CRS). The controversy surrounding the impact of allergic rhinitis on CRS continues, but it is reasonable to consider and treat allergic sources of inflammation in any patient with CRS. CRS is more severe in patients with aspirin sensitivity but improves--at least temporarily--to the same degree as in non-aspirin-sensitive patients, given appropriate therapy. Polypoid rhinosinusitis in cystic fibrosis patients is characterized by compromised mucociliary clearance and infection with staphylococcal and pseudomonal organisms. Affected individuals require frequent antibiotic treatment, saline lavage, and repeated surgeries. Rhinosinusitis is among the most common infectious complications of humoral immunodeficiency, which is not uncommon in patients with refractory CRS. The treatment approach in immunodeficiency includes aggressive antibiotic treatment and intravenous immunoglobulin. Specific diagnosis of comorbid systemic conditions with CRS will facilitate appropriate management.

show abstract

The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis

Cited by 28 publications

References 40 publications

ASS-Toleranzinduktion

ASS-Toleranzinduktion

Diagnosis and Management of Chronic Rhinosinusitis in Adults

Rhinosinusitis and Comorbidities

Contact Info

Product

Resources

About